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M. Aksoy,1* J.-P. Becquemin,2 P. Desgranges,2 E. Allaire2 and H. Kobeiter31Department of General Surgery, Medical Faculty of Istanbul, Istanbul, Turkey, Department of 2Vascular
Surgery, and 3Radiology, Henri Mondor Hospital, Creteil, FranceObjective. The aim of this study was to evaluate the safety and efficacy of the closure device Angioseal.
Material and methods. All consecutive patients, who underwent a therapeutic radiological intervention using the femoral
artery approach from January 2001 to January 2005 in the Service of Vascular Surgery, Henri Mondor Hospital, Creteil,
France, were prospectively included in the study. The efficacy of Angioseal was defined by the ability of the device to cover the
puncture site and stop bleeding. The safety was defined by the rate of complications.
Results. A total of 79 Angioseal devices were employed on 77 patients. There were 62 (78.5%)males and 17 (21.5%) females.
Themean age of the patients was 65.2G11.6 years (meanGSD). All Angioseal devices were deployed successfully. There were
62 (78.4%) 6F and 17 (21.6%) 8F sheaths employed during the procedures. There were two minor (2.5%) hematomas, one
(1.2%) major hematoma and one (1.2%) pseudoaneurysm after the procedure. The mean time of discharge from the hospital
was 2.1G1.8 (meanGSD) days. The patients were followed up for a mean of 9.0G9.3 (1–60 months) months.
Conclusions. Angioseal provides a safe and effective way of closing the femoral artery puncture site with acceptable
morbidity rates.Keywords: Closure devices; Angioseal; Vascular surgery; Radiology.Introduction
The traditional method of hemostasis following an
interventional vascular procedure is manual com-
pression. Puncture site complications include bleed-
ing, hematoma, vessel occlusion and pseudoaneurysm
formation. The prolonged duration of manual com-
pression and a prolonged bed rest leads to patient
discomfort.1,2
A number of vascular closure devices are avail-
able.3,4 Angioseal, which was introduced as a vascular
closure device in Europe in 1994 operate by compres-
sing the puncture site between an anchor and a
collagen plug.5
This study aimed to evaluate the efficacy and safety
of Angioseal in interventional radiological therapeutic
interventions of the peripheral arterial system.Material and Methods
All consecutive patients, who had undergone a
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in the Service of Vascular and Endocrine Surgery,
Henri Mondor Hospital, Creteil, France, were pro-
spectively included in the study. The data regarding
patient age, sex, demographics, and the use of
anticoagulants and antiplatelet agents were recorded.
The data concerning the procedural details such as the
size of the vascular sheath employed, type of
procedure performed, and indication for arteriogra-
phy was noted.
A positive history of hypertension was defined as
need for antihypertensive drugs or systolic blood
pressure 160 mm Hg or greater or diastolic blood
pressure 95 mm Hg or greater. A positive history of
hypercholesterolemia was defined as need for
cholesterol-lowering medication or serum cholesterol
concentration 5.0 mmol/L or greater. A positive
history of diabetes mellitus was defined as need for
glucose-lowering medication or (non-fasting) serum
glucose concentration of 11.0 mmol/L or greater.
Currents smokers and former smokers in the last
10 years were categorized as smokers. A positive
history of angina pectoris or previous cardiac
intervention, ischemia on ECG and the need for a
cardiac treatment were categorized as cardiac
disease.Eur J Vasc Endovasc Surg 32, 90–93 (2006)
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Table 1. Patients’ characteristics and risk factors
Hypertension 39 (49.3%)
Current smokers 22 (27.8%)
Hyperlipidemia 17 (21.5%)
Coronary heart disease 16 (20.2%)
Diabetes mellitus 9 (11.4%)
Bladder cancer 2 (2.5%)
Prostate cancer 1 (1.2%)
Hodgkin’s disease 1 (1.2%)
Larynx cancer 1 (1.2%)
Cirrhosis 1 (1.2%)
Femoral Artery Closure Devices 91Patients underwent percutaneous approach using
the standard Seldinger technique. The procedures
were performed in the operating theatre or in the
interventional radiology suite. Patients were prepped
with betadine before the intervention. Heparin
(0.5 IU/kg) was administered intravenously before
balloon dilatation or stent placement. The size of the
Angioseal devices was decided according to the
vascular sheath that was used. The puncture site was
closed with 6-French Angioseal after the use of 5F and
6F sheaths whilst 8FAngioseal device was used for 7F
sheaths. Patients were placed at bed rest for at least
30 min after use of the 6F device and 90 min following
use of the 8F device according to the product
representative recommendations.
The efficacy of Angioseal was defined by the ability
of the device to cover the puncture site and stop
bleeding. The safety was defined by the rate of
complications. Bleeding was defined by a hematoma
greater than 6 cm and a decrease in hemoglobin of
more than 1 g, as well as those requiring transfusion or
operation.Table 2. The details of the procedures, which have been performed
during the study period, are shown
Procedure Frequency Percent
Carotid and iliac artery 1 1.27
IliacCsuperficial femoral artery 1 1.27
Iliac artery 21 26.58
Lower limb revascularisation 16 20.25
Renal artery 10 12.66
Subclavian artery 2 2.53
Superior mesenteric artery 1 1.27
Vertebral artery 1 1.27
Total 79 100Results
A total of 79 Angioseal devices were employed on 77
patients during the study period. There were 62
(78.5%) males and 17 (21.5%) females. The mean age
of the patients was 65.2G11.6 years (meanGSD). Of 79
patients, 9 (11.4%) had diabetes, 39 (49.3%) had
hypertension, 17 (21.5%) had hyperlipidemia, 16
(20.2%) had coronary heart disease, and 22 (27.8%)
were current smokers. There were 2 (2.5%) patients
with bladder cancer, one patient (1.2%) with prostate
cancer, one patient (1.2%) with Hodgkin’s disease, one
patient (1.2%) with larynx cancer, and another patient
(1.2%) with cirrhosis Table 1. All patients were
receiving antiplatelet treatment at the time of the
intervention, whilst 2 (2.5%) of the patients were
receiving anticoagulant treatment. Thirty-five (44.3%)
patients were hospitalized for lower limb ischemia,
whilst 27 (34.2%) and 17 (21.5%) patients were
hospitalized for carotid stenosis and other causes,
respectively.
The procedures included iliac and lower limb
revascularization in 36 (45.5%) patients, cerebrovas-
cular procedures in 28 (35.4%), and renal angioplasty
and stenting in 10 (12.6%) patients. Two (2.5%) of the
patients underwent two separate interventions during
the procedure. The patients, who had undergone a
procedure for lower limb revascularization, included 3
(3.7%) patients that received fibrinolysis for anoccluded femoro-popliteal bypass. The details of the
procedures are shown in Table 2.
All Angioseal devices were deployed successfully.
There were 62 (78.4%) 6F and 17 (21.6%) 8F sheaths
employed during the procedures. There were two
minor (2.5%) hematomas and one (1.2%) major
hematoma after the procedure. The patient, who had
a major hematoma required two units of blood
transfusion but no surgical intervention. He also had
a pseudoaneurysm of 5 mm, which was demonstrated
by computerized tomography scanning. The pseudoa-
neurysm resolved at 1 month. Two patients suffered
from temporary renal insufficiency, which resolved
with hydration. The mean time of discharge from the
hospital was 2.1G1.8 (meanGSD) days (Table 2).
The patients were followed up for a mean of
9.0G9.3 (1–60 months) months. One patient, who
had chronic renal insufficiency and a lower extremity
ulcer died as a result of a septic shock 2 months after
the intervention. There were no local complications
during the follow-up period.Discussion
Endovascular interventions have become a commonly
accepted method of treatment in certain vascular
diseases. Access site complications may lead to
prolonged hospital stay and increased costs.1,6 Hemos-
tasis at the femoral artery access site is usually
achieved by manual compression followingEur J Vasc Endovasc Surg Vol 32, July 2006
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cedures. Although manual compression is effective in
achieving hemostasis in most cases, it requires a
15–20 min sustained compression over the puncture
site followed by prolonged rest.7 When manual
compression is used, a number of standard protocols
require a minimum of 4 h of bed rest following
diagnostic studies performed with 5F sheaths and a
minimum of 6 h of bed rest when larger sheaths are
used for therapeutic interventions.7 Upper extremity
fatigue and human resource considerations are other
disadvantages of the method.
The drawbacks of manual compression have led to
a search for a more comfortable methods of puncture
site hemostasis for both the physician and the patient.
The initial attempt was to reduce the sizes of catheters
and guidewires. This led to an decreased rate of groin
complications but the latest procedures in endovas-
cular surgery required larger sheaths.8,9 The frequent
use of antiplatelet or anticoagulant agents created a
tendency to bleeding in patients and an increase rate of
access site complications.10,–12 The first generation of
vascular closure devices was not very welcome since
these ‘unsophisticated’ devices were plagued with
significant complication rates.13 The design has under-
gone some significant changes in order to achieve a
safer and a more beneficial device. The Angioseal
device consists of an anchor composed of a polylactide
and polyglycolide polymer, a collagen plug, and
suture contained within a special carrier system.5
When inserted, it achieves hemostasis by compressing
the arterial puncture site between the anchor and
the collagen plug. The Angioseal can consistently
be deployed within 1 min, and is completely
bioabsorbable.
In our series, Angioseal was effective in achieving
hemostasis in 98.7% of the patients. One patient
developed a retroperitoneal hematoma, which
required two units of blood transfusion and had a
pseudoaneurysm of 5 mm at the puncture site on the
computerized tomography scan. However, the hema-
toma did not require further treatment than transfu-
sion and the pseudoaneurysm resolved spontaneously
at 1 month. The results of previous studies are in
accordance to ours, revealing Angioseal as an effective
and a safe method of femoral puncture site closure
device following interventional vascular procedures.
An efficacy of 95–100% exists in different reports.14 In a
recent report, which included 188 patients and 144
procedures, all but three of Angioseal devices were
deployed successfully.2 These results are satisfying
because manual compression was effective in achiev-
ing hemostasis without any further complications
in patients with failure of deployment. As well asEur J Vasc Endovasc Surg Vol 32, July 2006its efficacy, its safety is promoted by these reports
as complications such as infection, hemorrhage,
and vessel occlusion have been uncommon, ranging
from 0 to 1.9%.15–17 In the series of Abando et al.,2
which included 76 therapeutic interventions, there
were no significant bleeding complications or
infections.
Angioseal allowed early ambulation, rapid recov-
ery time, and decreased discomfort in our patients.
Hence, the patients may be more satisfied with safe
and effective closure devices. The mean time of
discharge of our patients was 2.1 days but this group
also included patients with diabetic foot ulcers.
Therefore, it included patients, who needed prolonged
hospitalization for local treatment. However, in 1-day
procedures, closure devices are supportive since
patients can be ambulated 1 h after the placement of
a 6F device, and within 3 h after placement of an 8F
device.2
In conclusion, we believe that Angioseal provides a
safe and effective way of closing the puncture site at
the femoral artery following an interventional thera-
peutic vascular approach.References
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